DOI: 10.1182/blood.2024028172 ISSN: 0006-4971
Cyclophosphamide mitigates non-ICANS neurotoxicities after ciltacabtagene autoleucel treatment
Viktoria Blumenberg, Benjamin R. Puliafito, Charlotte E Graham, Mark B. Leick, Md Raihan Chowdhury, Maxx King, Deshea L. Harris, Noopur S. Raje, Andrew R. Branagan, Andrew J. Yee, Diana D. Cirstea, Kathleen M.E. Gallagher, Jörg Dietrich, Marcela V. Maus, Matthew J. FrigaultPotentially fatal non-ICANS neurotoxicities (NINTs) following BCMA-targeted CAR T-cell therapy have been linked to high CAR T-cell expansion and prolonged persistence. Cyclophosphamide in an effort to ablate CAR T-cells is an effective treatment strategy to mitigate steroid-refractory courses of NINTs.